In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/asandeutertinib-tops-osimertinib-egfr-nsclc-brain-metastases-2026a1000i5p?src=rss
Author :
Publish date : 2026-06-01 12:01:00
Copyright for syndicated content belongs to the linked Source.